SPTX — Seaport Therapeutics, Inc. Common Stock stock price, charts and financials

QT85Seaport Therapeutics, Inc. Common Stock

Latest market price

23.55

-0.07-0.32%

Overview Short InterestFilings

SPTXQT85Seaport Therapeutics, Inc. Common Stock·NASDAQ

Overview Short InterestFilings

23.55-0.32%

Loading chart...

Screen all →

AUPH-2.33%$15.48 MESO+4.96%$16.73 ZBIO-1.46%$31.96 GHRS-2.07%$29.64 TSHA-0.69%$6.51 STOK-1.46%$32.23 ABCL+31.03%$9.08 VRDN-2.29%$23.05

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	31.17%	Shs Outstand	53.53M	Perf Week	15.44%

Market Cap	1.26B	Forward P/E	-	EPS next Y	-2.62	Insider Trans	0.00%	Shs Float	17.51M	Perf Month	15.16%

Enterprise Value	1.21B	PEG	-	EPS next Q	-0.71	Inst Own	-	Short Float	3.70%	Perf Quarter	52.39%

Income	-88.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	5.51	Perf Half Y	-

Sales	0.00	P/B	2.99	EPS next Y	41.89%	ROA	-19.93%	Short Interest	1.98M	Perf YTD	12.48%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-57.34%	52W High	24.40 -3.51%	Perf Year	-

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-21.83%	52W Low	14.80 59.06%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.33% 7.07%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-	Oper. Margin	0.00%	ATR (14)	1.50	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	18.00	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	66.00	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	18.00	EPS Q/Q	-	SMA20	12.65%	Beta	0.83	Target Price	43.33

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	20.04%	Rel Volume	0.56	Prev Close	23.62

Employees	54	LT Debt/Eq	-0.03	Earnings	Nov 02	SMA200	25.13%	Avg Volume	199.70K	Price	23.55

IPO Date	May 01, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-93.78% -	Net Debt/EBITDA	0.64	Volume	112,371	Change	-0.32%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Aug-04-26	Reiterated	HC Wainwright & Co.	Buy	$50
Jul-15-26	Initiated	H.C	Buy	$50
May-26-26	Initiated	Leerink	Outperform	$35
May-26-26	Initiated	Stifel	Buy	$30
May-26-26	Initiated	JPMorgan	Overweight	$42

Latest News

Aug-03-26

Aug-03-2607:05AM

Seaport Therapeutics Q2 EPS $(1.78) Misses $(0.65) EstimateBenzinga

07:00AM

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progressbusinesswire.com

Jul-15-26

Jul-15-2606:42AM

HC Wainwright & Co. Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $50Benzinga

Company

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)		FY 2025 12/31/2025
Total Revenue		0
Cost of Goods Sold Incl. D&A		0
Gross Profit		0
Selling, General and Administrative Excl. Other		21
Research and Development		66
Other Operating Expense		0
Operating Income		-87
Interest Expense		0
Unusual Expense		—
Non-Operating Income (Expense)		13
Net Income Before Taxes		-74
Income Taxes		1
Consolidated Net Income		-75
Net Income From Continuing Operations		-75
Net Income		-75
EPS (Recurring)		-1.94
EPS (Basic, Before Extraordinaries)		-1.94
EPS (Diluted)		-1.94
EBITDA		-86
Other After Tax Adjustments		—
Stock Option Compensation Expense		—
Price To Earnings Ratio		—
Price To Sales Ratio		—
Gross Margin		—
Operating Margin		—
Net Margin		—
Shares Outstanding		39
Market Capitalization		—
Operating Lease Expense		—

Insider Trading Volume

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.